BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17283170)

  • 1. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.
    Nava-Parada P; Forni G; Knutson KL; Pease LR; Celis E
    Cancer Res; 2007 Feb; 67(3):1326-34. PubMed ID: 17283170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.
    Ghaffari-Nazari H; Tavakkol-Afshari J; Jaafari MR; Tahaghoghi-Hajghorbani S; Masoumi E; Jalali SA
    PLoS One; 2015; 10(11):e0142563. PubMed ID: 26556756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.
    Cho HI; Niu G; Bradley N; Celis E
    Cancer Immunol Immunother; 2008 Nov; 57(11):1695-703. PubMed ID: 18253731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
    Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
    Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy.
    Rolla S; Ria F; Occhipinti S; Di Sante G; Iezzi M; Spadaro M; Nicolò C; Ambrosino E; Merighi IF; Musiani P; Forni G; Cavallo F
    J Immunol; 2010 Jun; 184(11):6124-32. PubMed ID: 20435927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
    Gritzapis AD; Voutsas IF; Baxevanis CN
    Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
    Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
    Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
    Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R; Paterson Y
    Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.
    Sharma S; Dominguez AL; Manrique SZ; Cavallo F; Sakaguchi S; Lustgarten J
    Cancer Res; 2008 Sep; 68(18):7530-40. PubMed ID: 18794141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.